Actinic Keratosis
Graceway Pharmaceuticals Reports Study in British Journal of Dermatology: Patients Treated with ALDARA Experienced Higher Levels of Histological and Sustained Clearance for Actinic Keratosis (AK) than Patients in two Other
Published in Health Business Week, May 2nd, 2008
Graceway Pharmaceuticals, LLC announced the results from a study comparing 3 different treatments for actinic keratosis, a skin condition that can become cancerous if left untreated. This study evaluated three common treatment options: imiquimod 5% cream (ALDARA), topical 5-fluorouracil (5-FU), and cryotherapy. The results of this study demonstrated that patients treated with ALDARA experienced the highest level of histological (biopsy confirmed) clearance among patients in the three treatment arms. In addition, 12 months after treatment, significantly more patients remained disease free with ALDARA than after treatment with cryotherapy or 5-FU. The design and detailed results of this...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
Source: Health Business Week (2008-05-02)
More Articles from Health Business Week
- Abbott
Innovative Diagnostic Instrument Introduced by Abbott for Low- to Mid-Volume Laboratory Market Segment - Abdominal Aortic Aneurysm
FDA Approves Medtronic's Talent(TM) Abdominal Stent Graft for Repairing Aortic Aneurysms - Acne Vulgaris
CLEAN & CLEAR(R) Introduces SOFT, a Moisturizing Line of Healthy Skincare Products Designed to Soften, Purify and Protect Young Skin - Acne Vulgaris
PartnerWeekly and SensiClear(TM) Sign Online Marketing Pact - ActiveCare Network LLC
ActiveCare Network LLC Offers Two Million Patients Convenient, Affordable Access to Chronic Biologic Services - Acute Lymphoblastic Leukemia
St. Jude Discovery Offers New Avenues to Understanding an Aggressive Form of Leukemia - More from this issue of Health Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
